SS&C GlobeOp Hedge Fund Performance Index: November performance 2.32%
Capital Movement Index:  December net flows advance 0.27%

WINDSOR, Conn., Dec. 12, 2024 /PRNewswire/ — SS&C Technologies Holdings, Inc. (Nasdaq: SSNC) today announced the gross return of the SS&C GlobeOp Hedge Fund Performance Index for November 2024 measured 2.32%.

Hedge fund flows as measured by the SS&C GlobeOp Capital Movement Index advanced 0.27% in December.

“SS&C GlobeOp’s Capital Movement Index finished 2024 with strong positive net flows for the calendar year. The normalization of longer-term trends is evident as we near the five-year anniversary of the start of the pandemic,” said Bill Stone, Chairman and Chief Executive Officer of SS&C Technologies. “December net flows were 0.27% compared to -0.47% for the same period a year ago, while the full year 2024 provided the most robust net capital flows since 2021. These results reflect continued interest in hedge fund strategies. Investors are seeking risk-adjusted returns with low correlations to complement their traditional equity and fixed income allocations.”

SS&C GlobeOp Hedge Fund Performance Index

The SS&C GlobeOp Hedge Fund Performance Index is an asset-weighted, independent monthly window on hedge fund performance. On the ninth business day of each month it provides a flash estimate of the gross aggregate performance of funds for which SS&C GlobeOp provides monthly administration services on the SS&C GlobeOp platform. Interim and final values, both gross and net, are provided in each of the two following months, respectively. Online data can be segmented by gross and net performance, and by time periods. The SS&C GlobeOp Hedge Fund Performance Index is transparent, consistent in data processing, and free from selection or survivorship bias.  Its inception date is January 1, 2006.

The SS&C GlobeOp Hedge Fund Performance Index offers a unique reflection of the return on capital invested in funds.  It does not overstate exposure to, or the contribution of, any single strategy to aggregate hedge fund performance. Since its inception, the correlation of the SS&C GlobeOp Performance Index to many popular equity market indices has been approximately 25% to 30%. This is substantially lower than the equivalent correlation of other widely followed hedge fund performance indices.

SS&C GlobeOp Capital Movement Index

The SS&C GlobeOp Capital Movement Index represents the monthly net of hedge fund subscriptions and redemptions administered by SS&C GlobeOp on the SS&C GlobeOp platform. This monthly net is divided by the total assets under administration (AuA) for fund administration clients on the SS&C GlobeOp platform.

Cumulatively, the SS&C GlobeOp Capital Movement Index for December 2024 stands at 125.42 points, an increase of 0.27 points over November 2024. The Index has declined 1.75 points over the past 12 months. The next publication date is January 14, 2024.

Published on the ninth business day of each month, the SS&C GlobeOp Capital Movement Index presents a timely and accurate view of investments in hedge funds on the SS&C GlobeOp administration platform. Data is based on actual subscriptions and redemptions independently calculated and confirmed from real capital movements, and published only a few business days after they occur. Following the month of its release, the Index may be updated for capital movements that occurred after the fifth business day.

SS&C GlobeOp Hedge Fund Performance Index

SS&C GlobeOp Capital Movement Index

SS&C GlobeOp Forward Redemption Indicator

About the SS&C GlobeOp Hedge Fund Index®
The SS&C GlobeOp Hedge Fund Index (the Index) is a family of indices published by SS&C GlobeOp. A unique set of indices by a hedge fund administrator, it offers clients, investors and the overall market a welcome transparency on liquidity, investor sentiment and performance. The Index is based on a significant platform of diverse and representative assets.

The SS&C GlobeOp Capital Movement Index and the SS&C GlobeOp Forward Redemption Indicator provide monthly reports based on actual and anticipated capital movement data independently collected from all hedge fund clients for whom SS&C GlobeOp provides administration services on the SS&C GlobeOp platform.

The SS&C GlobeOp Hedge Fund Performance Index is an asset-weighted benchmark of the aggregate performance of funds for which SS&C GlobeOp provides monthly administration services on the SS&C GlobeOp platform. Flash estimate, interim and final values are provided, in each of three months respectively, following each business month-end.

While individual fund data is anonymized by aggregation, the SS&C GlobeOp Hedge Fund Index data will be based on the same reconciled fund data that SS&C GlobeOp uses to produce fund net asset values (NAV). Funds acquired through the acquisition of Citi Alternative Investor Services are integrated into the index suite starting with the January 2017 reporting periods. SS&C GlobeOp’s total assets under administration on the SS&C GlobeOp platform represent approximately 10% of the estimated assets currently invested in the hedge fund sector. The investment strategies of the funds in the indices span a representative industry sample. Data for middle and back office clients who are not fund administration clients is not included in the Index, but is included in the Company’s results announcement figures.

About SS&C Technologies
SS&C is a global provider of services and software for the financial services and healthcare industries. Founded in 1986, SS&C is headquartered in Windsor, Connecticut, and has offices around the world. Some 20,000 financial services and healthcare organizations, from the world’s largest companies to small and mid-market firms, rely on SS&C for expertise, scale and technology.

Additional information about SS&C (Nasdaq: SSNC) is available at www.ssctech.com.

Follow SS&C on X, LinkedIn and Facebook.

View original content to download multimedia:https://www.prnewswire.com/news-releases/ssc-globeop-hedge-fund-performance-index-and-capital-movement-index-302329912.html

SOURCE SS&C

Founder of First Senolytic Based Regenerative Dermatology Company to Honored for Contributions

SAN DIEGO, Dec. 12, 2024 /PRNewswire/ — Robles BioCeutics announced today that its CEO, Maria Robles, has been selected as a finalist for the San Diego Business Journal’s Business Woman of the Year Award. 

Maria is recognized for her strong leadership and innovation in the field of regenerative dermatology and stem cell-based skin care solutions. 

“It is my honor to work with Maria and witness first-hand her talents at combining science and business, and always putting the patient first,” said Dr. Jorge Genovese, M.D., Ph.D, Chief Scientific Officer of Robles Bioceutics. “Under Maria’s leadership, the company created Glowselle, a patent-pending anti-aging cream that helps skin reverse in age using stem cell and senolytic technologies. Maria’s commitment to new ideas is setting high standards in the skin care industry.”

Robles BioCeutics has previously filed a patent on its proprietary methodologies involving “injury mimetics” which as used to stimulate toll like receptors in vitro to elicit most potent anti-aging products from stem cells ex vivo1.  The Company is currently collaborating with internationally renowned laboratories for identifying mechanisms of cellular dedifferentiation and senolytic activities as it advances towards clinical trials2.

“I am greatly honored to be selected by the San Diego Business Journal, one of the key industry specific publications,” said Maria Robles. “This is a testament to the excellent work and dedication of our team as we continue on this journey of developing science based skin care solutions.”

For more information about Robles BioCeutics and its mission to redefine beauty and aging, visit https://roblesbioceutics.com.  A video describing the Company us available at https://www.youtube.com/watch?v=97CXV7aqINQ. 

About Robles BioCeutics

Robles BioCeutics is a regenerative dermatology company committed to delivering science-driven solutions for skin health and aging. Founded by Maria Robles, the company is at the forefront of innovation with its flagship product, Glowselle, which redefines how women maintain their natural beauty and vitality.

For updates, follow Robles BioCeutics on Instagram, Twitter, Facebook, and Youtube, or visit https://roblesbioceutics.com.

Media Contact:
Maria Robles
CEO
Robles BioCeutics
858-609-0948
https://roblesbioceutics.com/
387606@email4pr.com 

1 https://www.prnewswire.com/news-releases/robles-bioceutics-files-landmark-patent-on-first-in-class-cosmetic-rejuvenation-product-glowselle-302261050.html
2 https://www.pharmabiz.com/NewsDetails.aspx?aid=173480&sid=2

View original content to download multimedia:https://www.prnewswire.com/news-releases/robles-bioceutics-ceo-maria-robles-named-finalist-for-san-diego-business-woman-of-the-year-302330305.html

SOURCE Robles BioCeutics

This long-term innovation partnership enables new care models for hospital monitoring in Denmark.

COPENHAGEN, Denmark and CHICAGO, Dec. 12, 2024 /PRNewswire/ — The Capital Region of Denmark has selected Sibel Health, an award-winning medical technology company spun out of the Querrey-Simpson Institute for Bioelectronics at Northwestern University, for a long-term innovation partnership along with Dräger to deploy advanced continuous monitoring in the hospital setting after a highly competitive, multi-year global selection process. Sibel Health manufactures the FDA-cleared ANNE® One monitoring platform powered by clinical-grade wearables for all vital signs. For the Capital Region of Denmark, new monitoring technologies are needed to address staffing shortages, an increase in patient load, and the move to single rooms. This novel tendering process using the EU innovation partnership format provides a completely new model for procurement—a focus on the problem first, in an open, rigorously competitive process. After a collaborative joint innovation phase, the final solution will be deployed in multiple leading Copenhagen area hospitals.

“We are deeply honored for Sibel Health and our ANNE® One monitoring platform with advanced medical wearables to be selected by the Capital Region of Denmark. The future of monitoring centers on technology that surveils a patient condition wirelessly and continuously, reduces physical and cognitive load for nurses, and seamlessly integrates with hospital IT infrastructure. We look forward to ensuring the solution fits the needs of the Capital Region of Denmark perfectly,” says Steve Xu MD, CEO and co-founder of Sibel Health.

“Sibel Health, in close collaboration with Dräger, will ensure that the Capital Region of Denmark’s deep knowledge of their clinical workflows and staff challenges will translate to technology implementation that can monitor patients’ vital signs automatically and appropriately escalate notifications to staff, “says Line Vibe, Head of Hospital Segment in Dräger Denmark. Brian Holch Kristensen, Chief Innovation Officer of Bispebjerg Hospital, notes “it is only through close collaboration and new models of procurement that we can solve the most challenging problems in healthcare. Sibel Health had a proposal that enabled co-creation that clinicians trusted to give the best future integrated health care solution.” Anders Hoffmeyer Uhre, innovation consultant in the Department for Quality and Education at Bispebjerg and Frederiksberg Hospital, notes “Sibel Health had a technological solution that surprised the clinicians and the broader team by being a vital part in a fully integrated solution towards solving the clinical need.” One of the core values at Sibel is always putting patients first—we look forward to moving in, listening, and collaboratively working with experts at Bispebjerg and Frederiksberg Hospitals to deliver a solution that both benefits patients and works seamlessly for their clinicians,” adds Kelly Cao, Head of Design at Sibel Health.

After the innovation sprint, the collaboration moves to a 4-year purchase agreement and installation in more than 1,000 hospital beds at a total estimated purchase value in excess of $20 million USDs (141 million DKK). The solution provided by Sibel is also expected to then be used in other Danish regions beyond the Capital over a subsequent 10-year period at a total estimated purchase value in excess of $100 million USDs (706 million DKK). “Sibel Health will be establishing a base of operations here in Copenhagen in order to succeed as a long-term partner in this innovation collaboration, and ensure success of the ultimate medical monitoring installation,” says JooHee Lee, Senior Product Manager and co-founder of Sibel Health.

About Sibel Health. Better Health Data for All®
Sibel Health is an award-winning medical technology company based in Chicago (USA) with an international office in Seoul (South Korea). The company’s FDA-cleared ANNE® One platform includes advanced wearable sensors, AI-enabled data analytics, and an integrated mobile software and cloud platform. Sibel has partnerships with some of the most respected healthcare organizations worldwide. For more information, please visit us at www.sibelhealth.com and follow us on LinkedIn.

About Dräger. Technology for Life®
Dräger is an international leader in the fields of medical and safety technology. Our products protect, support, and save lives. Founded in 1889, Dräger generated revenues of around €3.4 billion in 2023. The Dräger Group is currently present in over 190 countries and has more than 16,000 employees worldwide. Please visit www.draeger.com for more information.

Photo – https://mma.prnewswire.com/media/2578817/Sibel_Health_Denmark.jpg
Logo – https://mma.prnewswire.com/media/1872675/Sibel_Health_Logo.jpg 

View original content:https://www.prnewswire.co.uk/news-releases/sibel-health-selected-to-provide-continuous-wireless-monitoring-to-the-capital-region-of-denmark-302329232.html